{"id":556710,"date":"2026-06-03T12:30:00","date_gmt":"2026-06-03T10:30:00","guid":{"rendered":"https:\/\/medizinonline.com\/?p=556710"},"modified":"2026-06-03T13:06:59","modified_gmt":"2026-06-03T11:06:59","slug":"recidive-apres-inhibition-de-btk-facteurs-pronostiques-et-options-therapeutiques","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/recidive-apres-inhibition-de-btk-facteurs-pronostiques-et-options-therapeutiques\/","title":{"rendered":"R\u00e9cidive apr\u00e8s inhibition de BTK &#8211; facteurs pronostiques et options th\u00e9rapeutiques"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Le lymphome des cellules du manteau (MCL) est un lymphome non hodgkinien \u00e0 cellules B rare dont l&#8217;\u00e9volution est particuli\u00e8rement h\u00e9t\u00e9rog\u00e8ne. L&#8217;\u00e9ventail va des formes indolentes et lentement progressives aux variantes tr\u00e8s agressives. Le diagnostic et le traitement restent exigeants, car la pr\u00e9sentation clinique, les marqueurs mol\u00e9culaires et la r\u00e9ponse au traitement varient consid\u00e9rablement. Les nouvelles th\u00e9rapies cibl\u00e9es et les projets de registres internationaux am\u00e9liorent de plus en plus le pronostic, m\u00eame si le MCL reste une maladie complexe.   <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Frecidive-apres-inhibition-de-btk-facteurs-pronostiques-et-options-therapeutiques%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Le lymphome des cellules du manteau (MCL) est un lymphome non hodgkinien \u00e0 cellules B rare dont l&#8217;\u00e9volution est particuli\u00e8rement h\u00e9t\u00e9rog\u00e8ne. L&#8217;\u00e9ventail va des formes indolentes et lentement progressives aux&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Frecidive-apres-inhibition-de-btk-facteurs-pronostiques-et-options-therapeutiques%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":556711,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Lymphome des cellules du manteau","footnotes":"","_members_access_role":[],"_members_access_error":""},"category":[11549,11531,11373,11389],"tags":[92849,92833,92829,92853,92851,92838,46174,34713,92846,92845,92850,92857,37067,92858,92856,37079,92852,92855,92841,92832,92847,92844,92848,92830,92831,92835,92840,92842,92839,92854,92836,92834,92837,92843],"powerkit_post_featured":[],"class_list":["post-556710","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-fr","category-formation-continue","category-hematologie","category-oncologie","tag-acalabrutinib","tag-blocage-de-bcl2","tag-chimio-immunotherapie-mcl","tag-diagnostic-mcl","tag-evolution-heterogene-mcl","tag-facteurs-pronostiques-mcl","tag-histologie-fr","tag-ibrutinib-fr","tag-immunophenotypage","tag-indice-de-proliferation-du-ki-67","tag-inhibiteurs-de-btk-2","tag-inhibition-de-la-btk","tag-lymphome-des-cellules-du-manteau","tag-lymphome-des-cellules-du-manteau-2","tag-lymphome-non-hodgkinien-a-cellules-b-2","tag-mcl-fr","tag-mcl-agressif","tag-mcl-indolent","tag-mutation-tp53-mcl","tag-pet-ct-mcl","tag-pirtobrutinib","tag-recidive-apres-inhibition-de-la-btk","tag-recidive-de-mcl","tag-registre-emcl","tag-schema-de-traitement-glove","tag-schema-glove","tag-score-mipi","tag-statut-sox11","tag-surexpression-de-la-cycline-d1","tag-therapie-mcl","tag-traitement-par-anticorps-cd20","tag-translocation-t1114","tag-transplantation-autologue-de-cellules-souches-mcl","tag-zanubrutinib","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-07-22 14:29:44","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":556707,"slug":"recidiva-dopo-linibizione-di-btk-fattori-prognostici-e-opzioni-di-trattamento","post_title":"Recidiva dopo l'inibizione di BTK - fattori prognostici e opzioni di trattamento","href":"https:\/\/medizinonline.com\/it\/recidiva-dopo-linibizione-di-btk-fattori-prognostici-e-opzioni-di-trattamento\/"},"pt_PT":{"locale":"pt_PT","id":556702,"slug":"recorrencia-apos-inibicao-da-btk-factores-de-prognostico-e-opcoes-de-tratamento","post_title":"Recorr\u00eancia ap\u00f3s inibi\u00e7\u00e3o da BTK - factores de progn\u00f3stico e op\u00e7\u00f5es de tratamento","href":"https:\/\/medizinonline.com\/pt-pt\/recorrencia-apos-inibicao-da-btk-factores-de-prognostico-e-opcoes-de-tratamento\/"},"es_ES":{"locale":"es_ES","id":556698,"slug":"recurrencia-tras-la-inhibicion-de-la-btk-factores-pronosticos-y-opciones-de-tratamiento","post_title":"Recurrencia tras la inhibici\u00f3n de la BTK: factores pron\u00f3sticos y opciones de tratamiento","href":"https:\/\/medizinonline.com\/es\/recurrencia-tras-la-inhibicion-de-la-btk-factores-pronosticos-y-opciones-de-tratamiento\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/556710","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=556710"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/556710\/revisions"}],"predecessor-version":[{"id":556712,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/556710\/revisions\/556712"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/556711"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=556710"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=556710"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=556710"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=556710"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}